This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...
Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...
Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...
Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...
Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase ...
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...
Although the first GLP-1 drug was approved by the US Food and Drug Administration (FDA) in the early 2000s, it wasn't until a ...
This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.
Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...
A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.
The National Association of Attorneys General has submitted a letter to the U.S. Food and Drug Administration, signed by a ...
8h
HealthDay on MSNWeight-Loss Drugs Could Help Extend Life of Replacement JointsEven slight weight loss spurred on by cutting-edge GLP-1 drugs can help prevent replacement knees and hips from wearin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results